Hangzhou Solipharma Technology Development Co., Ltd. announced that it will receive CNY 69,485,700 in an equity round of funding on December 28, 2023. The transaction will include participation from returning investors Hangzhou Huolongguo Investment Management Co., Ltd. for CNY 4,904,622 out of which CNY 400,000 will go towards registered capital and will hold 37.2895% stake in the company, Sichuan Goldstone Asia Pharmaceutical Inc. for CNY 4,265,506 out of which CNY 1,261,629 will go towards registered capital and CNY 66,706,272 added as capital reserve and will hold 32.4304% stake in the company and individual investor Gao Yaping for CNY 3,779,224 out of which CNY 1,117,799 will go towards registered capital and will hold 28.7332% stake in the company. The registered capital is increased from CNY 10,373,386 to CNY 13,152,814.

The transaction has been approved by the company?s 5th directorate during its 2nd meeting.